% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mair:301768,
      author       = {M. J. Mair and P. Lohmann and N. Galldiks and M. Belting
                      and P. Brandal and M. P. G. Broen and F. Cicone and J.-F.
                      Daisne and F. Ducray and F. Ehret$^*$ and J. Furtner and A.
                      S. Jakola and M. Niyazi and A. Pellerino and M. Rasschaert
                      and E. Razis and F. Sahm$^*$ and M. Smits and N. Tolboom and
                      A. Verger and E. Le Rhun and G. Minniti and M. Weller and M.
                      Preusser and N. L. Albert},
      title        = {{A}vailability and use of {PET} in patients with brain
                      tumours - a {E}uropean {O}rganisation for {R}esearch and
                      {T}reatment of {C}ancer - {B}rain {T}umour {G}roup
                      ({EORTC}-{BTG}) survey.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {nn},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2025-01148},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Positron emission tomography (PET) is increasingly used in
                      neuro-oncology. However, little is known about its
                      application across European institutions and reasons for
                      variable implementation.Between June and August 2024,
                      members of the European Organisation for Research and
                      Treatment of Cancer - Brain Tumour Group (EORTC-BTG)
                      completed a cross-sectional online survey on PET use in
                      neuro-oncological practice.Overall, 103 replies from 20
                      countries were received. A PET facility was available at
                      96/103 $(93.2\%)$ sites, of whom 74 $(77.1\%)$ performed PET
                      in patients with brain tumours. Reasons for not performing
                      PET included limited availability of tracers (14/29,
                      $48.3\%),$ high cost (11/29, $37.9\%),$ and PET perceived
                      unnecessary (8/29, $27.6\%).$ Of sites performing PET, 69/74
                      $(93.2\%)$ reported use in glioma, 58/74 $(78.4\%)$ in brain
                      metastasis, 52/74 $(70.3\%)$ in meningioma, and 46/74
                      $(62.2\%)$ in CNS lymphoma. Amino acid PET was performed at
                      62/71 centres $(87.3\%;$ 3 not reported [n.r.]), most
                      frequently in glioma (58/59, $98.3\%,$ 3 n.r.) and for
                      differentiation of treatment-related changes from tumour
                      progression (58/59, $98.3\%).$ Somatostatin receptor (SSTR)
                      PET was performed at 50/68 sites $(73.5\%,$ 6 n.r.), mainly
                      in meningioma (48/49, $98.0\%),$ for patient selection
                      before radioligand therapy (41/49, $83.7\%)$ and for
                      radiotherapy target volume definition (33/49, $67.3\%).$
                      Unrestricted coverage by statutory health insurance was
                      reported by 46/59 $(78.0\%)$ centres for amino acid PET and
                      33/49 $(67.3\%)$ for SSTR PET.PET use in neuro-oncology is
                      variable across EORTC-BTG sites. Generation of evidence in
                      clinical trials and surveys including non-academic
                      institutions are needed to guide implementation in clinical
                      practice.},
      keywords     = {Brain metastasis (Other) / Glioma (Other) / Imaging (Other)
                      / Meningioma (Other) / Positron emission tomography (Other)},
      cin          = {BE01 / B300 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)B300-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40464806},
      doi          = {10.1007/s00259-025-07366-0},
      url          = {https://inrepo02.dkfz.de/record/301768},
}